B-cell acute lymphoblastic leukemia · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cytarabine, Idarubicin, Imatinib Variant #01 | BCR::ABL1 | R 32 629 | 5d | — | — | ~1 | ~R 32 629 indirect | — |
Cyclophosphamide, Daunorubicin, L-Asparaginase, Vincristine, Prednisone Variant #04 Partial | — | R 29 539 | 28d | — | — | ~1 | ~R 29 539 indirect | — |
Cytarabine and Idarubicin Variant #01 | — | R 12 853 | 30d | — | — | ~1 | ~R 12 853 indirect | — |
Cyclophosphamide, Cytarabine, Pegaspargase, Thioguanine, Vincristine, Dexamethasone Variant #01 Partial | — | R 9 708 | 50d | — | — | ~1 | ~R 9 708 indirect | — |
POMP Variant #01 | — | R 9 449 | 30d | — | — | ~24 | ~R 226 776 indirect | — |
CALGB 8811 late intensification Variant #01 | — | R 8 691 | 56d | — | — | ~1 | ~R 8 691 indirect | — |
6 of 6 regimens shown